Silexion Therapeutics LTD

1.00
-0.04 (-3.85%)
At close: Apr 02, 2025, 3:59 PM
0.99
-0.64%
After-hours: Apr 02, 2025, 06:33 PM EDT
-3.85%
Bid 0.97
Market Cap 8.69M
Revenue (ttm) n/a
Net Income (ttm) n/a
EPS (ttm) -26.36
PE Ratio (ttm) -0.04
Forward PE -3.17
Analyst Buy
Ask 1.02
Volume 206,267
Avg. Volume (20D) 14,291,053
Open 1.02
Previous Close 1.04
Day's Range 0.96 - 1.04
52-Week Range 0.21 - 13.56
Beta 0.11

About SLXN

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, ...

Industry Biotechnology
Sector Healthcare
IPO Date Aug 16, 2024
Employees NaN
Stock Exchange NASDAQ
Ticker Symbol SLXN
Full Company Profile

Analyst Forecast

According to 1 analyst ratings, the average rating for SLXN stock is "Buy." The 12-month stock price forecast is $5, which is an increase of 400.00% from the latest price.

Stock Forecasts
4 weeks ago
+30.63%
Silexion Therapeutics shares are trading higher af... Unlock content with Pro Subscription
1 month ago
+64%
Silexion therapeutics shares are trading higher after the company announced the completion of its initial study in orthotopic pancreatic cancer models evaluating systemic administration of SIL-204.